Question for the board: Is TNBC as an indication factored into the current stock price at all? For example, if results from the TNBC trial were to show no reduction in circulating tumor cells (I.e. leronlimab doesn’t work in TNBC), would there be a drop in the SP? I feel as if there were to be a drop, it would be minimal as the SP at this point is based mostly on HIV combo and mono.